4SC-203


CAS No. : 895533-09-2

4SC-203,895533-09-2
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000080
Synonyms:SC71710
Molecular Formula:C33H38N8O4S
Molecular Weight:642.77
Target:Multikinase inhibitor
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:I000080
Cas No:895533-09-2
Product-Name:4SC-203
InChI:InChI=1S/C33H38N8O4S/c1-21-6-9-27(43-3)26(16-21)37-32(42)39-33-38-24-8-7-22(17-30(24)46-33)36-31-23-18-28(44-4)29(19-25(23)34-20-35-31)45-15-5-10-41-13-11-40(2)12-14-41/h6-9,16-20H,5,10-15H2,1-4H3,(H,34,35,36)(H2,37,38,39,42)
InChIKey:MAFACRSJGNJHCF-UHFFFAOYSA-N
SMILES:O=C(NC1=NC2=CC=C(NC3=C4C=C(OC)C(OCCCN5CCN(C)CC5)=CC4=NC=N3)C=C2S1)NC6=CC(C)=CC=C6OC
4SC-203(SC71710, cas 895533-09-2) is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis. 4SC-203 had been in Phase I clinical study, however, this study was discontinued.

1: Williams R. Discontinued in 2013: oncology drugs. Expert Opin Investig Drugs. 2015 Jan;24(1):95-110. Epub 2014 Oct 14. PubMed PMID: 25315907.
Related Products
  • CAS No. :1130115-44-4
    Product Name:

    Sorafenib-d3

    Cat No: R006046 View details